Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients.
We report the long-term outcome of 27 HIV-infected patients treated for over 3 years with IL-2 and binucleoside analogues. These patients experienced a sustained increase in CD4 cells and a decrease of proviral DNA with infrequent IL-2 cycles. In three cases, virus could not be isolated from activated peripheral cells. A high frequency of HIV-1-specific memory CD4 T cells was found in the patients studied. IL-2 maintains specific effector cells and reduces the pool of infected cells in patients, albeit treated only with binucleosides.
Gougeon
M L
ML
Département SIDA et Rétrovirus, Institut Pasteur, Paris, France.
Rouzioux
C
C
Liberman
I
I
Burgard
M
M
Taoufik
Y
Y
Viard
J P
JP
Bouchenafa
K
K
Capitant
C
C
Delfraissy
J F
JF
Levy
Y
Y
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004279:DNA, Viral / Q000097:blood; D016049:Didanosine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007156:Immunologic Memory; D007376:Interleukin-2 / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004279:DNA, Viral; D007376:Interleukin-2; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016049:Didanosine